The market of biologics is growing at a nearly twice the rate of pharma as a whole. Biologics are expected to account for approximately 17% of total global spending on medicines by 2016, and reach an overall market value of $200 billion to $210 billion in 2016, up from $157 billion in 2011. Seven of the top 10 global medicines by spending will be a biologic within the next 5 years.
Biobetters: Challenges and Opportunities
Please join PRA Health Sciences' Dr. Hazel Gorham as she talks with PharmaVoice about what a biobetter is, how biobetters compare to biosimilars,…
Our collaborative, cross-functional team develops tailored, cost-effective services to meet the unique needs of biosimilars clinical development.
Biosimilars Newsletter Volume 3, July 2014
Welcome to the third edition of Biosimilars Newsletter, a quarterly publication dedicated to keeping you updated on current biosimilars news,…